Skip to content

Qi righting herbs combined with chemotherapy for advanced non -small cell lung cancer , randomized, double-blind, parallel-group study

Qi righting herbs combined with chemotherapy for advanced non-small cell lung cancer the clinical ef

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14005192
Enrollment
Unknown
Registered
2014-09-04
Start date
2014-09-04
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Yupingfeng group:Chemotherapy plus side Yupingfeng
Yiqiyangyin group:Chemotherapy plus Qi supplementing and Yin nourish
The control group:Chemotherapy plus Qi supplementing and Yin nourish

Sponsors

Shanghai Chinese medicine hospital ethics committee
Lead Sponsor

Eligibility

Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.By pathological or cytological examination confirmed the diagnosis of patients with stage III or IV non-small cell lung cancer; 2.Between the ages of 18 to 75 years of age (18, 75); 3.Expected lifetime more than six months; 4.The Karnofsky score equal and more than 60 points; 5.Within a month without radiation and chemotherapy; 6.Voluntary to participate in this study, to follow-up.

Exclusion criteria

Exclusion criteria: 1.Patients with other diseases, such as cardiac function, renal insufficiency, respiratory dysfunction and other major diseases; 2.Patients had received a immunotherapy or used glucocorticoid nearly three months; 3.Patients with other immune diseases; 4.Women during pregnancy or lactation;5.Patients with other factors such as decline in cognitive functions can't normal communication; 6. Patients can't accept chemotherapy; 7.Don't want to cooperate with the researcher; 8.Have allergy history or not according to stipulations incomplete in information; 9.Patients do not meet the inclusion criteria.

Design outcomes

Primary

MeasureTime frame
Quality of life scores;Improvement of symptoms;immune globulin;natural killer cell;T regulatory cell;B lymphocytes;T-lymphocytes;TGF-Beta;Routine blood test;Liver function;Renal functio;

Secondary

MeasureTime frame
tumor markers;Circulating peripheral blood of patients with lung;

Countries

China

Contacts

Public ContactLi Yan
18916767226@163.com+86 18916767226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026